Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $17.22 billion. The enterprise value is $11.31 billion.
Important Dates
The next confirmed earnings date is Friday, February 13, 2026, before market open.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 390.73 million shares outstanding. The number of shares has increased by 1.31% in one year.
| Current Share Class | 390.73M |
| Shares Outstanding | 390.73M |
| Shares Change (YoY) | +1.31% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 6.71% |
| Owned by Institutions (%) | 71.21% |
| Float | 364.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.66 |
| Forward PS | 8.92 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.93 |
| Quick Ratio | 3.51 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -432.88 |
Financial Efficiency
Return on equity (ROE) is -29.32% and return on invested capital (ROIC) is -65.53%.
| Return on Equity (ROE) | -29.32% |
| Return on Assets (ROA) | -15.49% |
| Return on Invested Capital (ROIC) | -65.53% |
| Return on Capital Employed (ROCE) | -33.13% |
| Weighted Average Cost of Capital (WACC) | 10.30% |
| Revenue Per Employee | $384,828 |
| Profits Per Employee | -$537,241 |
| Employee Count | 5,800 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 12.46 |
Taxes
| Income Tax | -37.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.23% in the last 52 weeks. The beta is 1.17, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +8.23% |
| 50-Day Moving Average | 33.29 |
| 200-Day Moving Average | 28.59 |
| Relative Strength Index (RSI) | 58.63 |
| Average Volume (20 Days) | 14,736,595 |
Short Selling Information
The latest short interest is 70.27 million, so 17.98% of the outstanding shares have been sold short.
| Short Interest | 70.27M |
| Short Previous Month | 68.32M |
| Short % of Shares Out | 17.98% |
| Short % of Float | 19.29% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
In the last 12 months, Moderna had revenue of $2.23 billion and -$3.12 billion in losses. Loss per share was -$8.05.
| Revenue | 2.23B |
| Gross Profit | -2.40B |
| Operating Income | -3.46B |
| Pretax Income | -3.15B |
| Net Income | -3.12B |
| EBITDA | -3.26B |
| EBIT | -3.46B |
| Loss Per Share | -$8.05 |
Full Income StatementBalance Sheet
The company has $4.50 billion in cash and $734.00 million in debt, with a net cash position of $5.91 billion or $15.13 per share.
| Cash & Cash Equivalents | 4.50B |
| Total Debt | 734.00M |
| Net Cash | 5.91B |
| Net Cash Per Share | $15.13 |
| Equity (Book Value) | 9.33B |
| Book Value Per Share | 23.86 |
| Working Capital | 4.92B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.98 billion and capital expenditures -$675.00 million, giving a free cash flow of -$2.65 billion.
| Operating Cash Flow | -1.98B |
| Capital Expenditures | -675.00M |
| Free Cash Flow | -2.65B |
| FCF Per Share | -$6.79 |
Full Cash Flow StatementMargins
Gross margin is -107.62%, with operating and profit margins of -155.15% and -139.61%.
| Gross Margin | -107.62% |
| Operating Margin | -155.15% |
| Pretax Margin | -141.26% |
| Profit Margin | -139.61% |
| EBITDA Margin | -145.83% |
| EBIT Margin | -155.15% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.31% |
| Shareholder Yield | -1.31% |
| Earnings Yield | -18.10% |
| FCF Yield | -15.41% |
Dividend DetailsAnalyst Forecast
The average price target for Moderna is $32.75, which is -25.69% lower than the current price. The consensus rating is "Hold".
| Price Target | $32.75 |
| Price Target Difference | -25.69% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 15.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 3.5 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | 1 |
